首页BLUE • NASDAQ
add
bluebird bio Inc
昨日收盘价
$7.80
当日价格范围
$7.40 - $8.24
年度波幅
$5.80 - $38.40
市值
7379.16万 USD
平均交易量
36.51万
市盈率
-
股息率
-
主要交易所
NASDAQ
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 1061.20万 | -14.36% |
经营支出 | 6293.90万 | -36.60% |
净收入 | -6080.80万 | 30.29% |
净利润率 | -573.01 | 18.60% |
每股收益 | -6.20 | 53.03% |
息税折旧摊销前利润 | -4876.40万 | 44.96% |
有效税率 | 0.10% | — |
资产负债表
总资产
负债总额
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 7065.10万 | -59.46% |
总资产 | 4.65亿 | -24.21% |
负债总额 | 4.71亿 | 20.40% |
权益总额 | -578.60万 | — |
发行在外的股份 | 972.22万 | — |
市净率 | -13.00 | — |
资产回报率 | -31.73% | — |
资本回报率 | -39.19% | — |
现金流
现金净变动
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -6080.80万 | 30.29% |
来自运营的现金 | -6892.80万 | -37.72% |
投资现金 | 46.60万 | -99.25% |
融资现金 | -610.50万 | 48.42% |
现金净变动 | -7456.70万 | -38,339.49% |
自由现金流 | -4844.48万 | 22.76% |
简介
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders.
The company's only - in the European Union - approved drug is betibeglogene autotemcel, which treats transfusion-dependent beta thalassemia, a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.
The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors. Wikipedia
CEO
成立时间
1992年4月16日
员工数量
282
